MediWound (NASDAQ:MDWD) Rating Lowered to "Strong Sell" at Zacks Research

Key Points

• MediWound has been downgraded to a "strong sell" rating by Zacks Research, further worsening its outlook among analysts.
• The company reported a quarterly loss of ($1.23) per share, missing expectations significantly, alongside a negative net margin of 142.18%.
• Despite recent downgrades, MediWound’s stock has seen some trading activity with a market capitalization of approximately $204.78 million.

MediWound (NASDAQ:MDWD - Get Free Report) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Several other research analysts have also recently commented on MDWD. Weiss Ratings reissued a "sell (d-)" rating on shares of MediWound in a research note on Wednesday, October 8th. Wall Street Zen cut MediWound from a "hold" rating to a "sell" rating in a research note on Friday, July 18th. Four equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $32.25.

MediWound Trading Up 1.4%

Shares of NASDAQ MDWD opened at $18.47 on Monday. MediWound has a twelve month low of $14.14 and a twelve month high of $22.50. The stock has a fifty day simple moving average of $17.60 and a 200-day simple moving average of $18.51. The stock has a market capitalization of $204.78 million, a PE ratio of -7.00 and a beta of 0.27.

MediWound (NASDAQ:MDWD - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.68). MediWound had a negative net margin of 142.18% and a negative return on equity of 96.71%. The firm had revenue of $5.71 million during the quarter, compared to analyst estimates of $5.68 million. On average, equities analysts predict that MediWound will post -2.66 earnings per share for the current year.

Institutional Trading of MediWound

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sheets Smith Investment Management purchased a new position in MediWound during the third quarter worth $362,000. Silverberg Bernstein Capital Management LLC increased its position in MediWound by 17.1% during the third quarter. Silverberg Bernstein Capital Management LLC now owns 172,816 shares of the biopharmaceutical company's stock worth $3,114,000 after buying an additional 25,281 shares in the last quarter. Jane Street Group LLC purchased a new position in MediWound during the second quarter worth $295,000. The Manufacturers Life Insurance Company increased its position in MediWound by 104.4% during the second quarter. The Manufacturers Life Insurance Company now owns 26,062 shares of the biopharmaceutical company's stock worth $505,000 after buying an additional 13,312 shares in the last quarter. Finally, Menora Mivtachim Holdings LTD. purchased a new stake in shares of MediWound in the second quarter valued at $339,000. 46.83% of the stock is owned by hedge funds and other institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.